[Adjuvant chemotherapy for osteogenic sarcoma: analysis of the present situation and of factors which have influenced therapeutic results].
Although it has been used for more than ten years, the value of chemotherapy as an adjunct to surgery has not yet been firmly established. Uncertainties are related to the multiplicity of factors involved in disease progression, management, and evaluation of results. Therefore, it is important to know the results of ongoing or terminated therapeutic trials, in order to propose new guidelines for research and for improvement of therapeutic results. The purpose of this article is to analyse the published results from historical controls (USA and Europe), and the results obtained using chemotherapy in the most significant series reported, as well as a series of twenty-six cases treated by the GESO (Osteogenic Sarcoma Study Group) following two different programs. The results in this group are similar to results in classical historical controls and in therapeutic trials reported by other spanish centers, although they are worse than those recorded in our own historical controls retrospectively analysed. It seems that in our patients unfavorable prognostic factors are predominant so that our results are worse than those from other series. Therefore, new controlled trials are needed, with adequate grouping of cases, using a different preoperative chemotherapy regimen, and comparing results to those in control groups without further treatment.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000628:therapy; D011184:Postoperative Period; D011292:Premedication; D013997:Time Factors
D000970:Antineoplastic Agents
La chimiothérapie adjuvante de l'ostéosarcome: analyse de la situation actuelle et des facteurs influant sur les résultats thérapeutiques.